Vital Signs Camera Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Respiration Rate
- Sponsor
- Philips Clinical & Medical Affairs Global
- Enrollment
- 94
- Locations
- 1
- Primary Endpoint
- Clinical safety and effectiveness VSC-MEDlib according to IFU
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This study is a single center, prospective clinical investigation which is balanced for gender, age, Body Mass Index (BMI) and skin color. Simultaneous measurements of PR and RR on study participants will be collected in conditions described in IFU and various suboptimal conditions. The study participants will be recorded with the VSC demo app (together with a compatible camera and computing hardware) and reference devices. PR and RR data to be collected by the VSC demo app, will be post-processed after the clinical investigation and compared with the reference devices. Persons who are willing to participate will be asked to provide their consent.
Primary objective:
• To assess the clinical safety and effectiveness of Pulse Rate (PR) and Respiration Rate (RR) measured with the VSC-MEDlib within the intended use compared to the gold-standard reference devices.
Exploratory objective:
• To assess the clinical safety and effectiveness of Pulse Rate and Respiration Rate measured with the VSC-MEDlib during suboptimal circumstances (outside the scope of the intended use), compared to the gold-standard reference devices.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Persons with ASA I or II classification
- •Adult population (age \>18 years old)
- •BMI ≥ 18 - ≤ 40 kg/m2
- •Able to intensively exercise for 10 minutes
- •Persons willing to give informed consent
- •Willingness to have vital signs measured by a medical mobile application
- •Willingness to follow study protocol (e.g., put on sunglasses, facial make-up, medical face-mask and sitting still up to 2 minutes)
Exclusion Criteria
- •Vulnerable populations (e.g., age \<18 years old, not able to consent by themselves, or immunecompromised or pregnant women)
- •Cardiac arrhythmias (e.g., Atrial Fibrillation, Supraventricular Tachycardia, Ventricular arrhythmia, regular ectopic beats)
- •Persons present signs of infection
- •Participant has known allergic reactions to make-up and/or make-up remover
- •Persons with positive COVID 19 test in last 14 days
- •Participant who exhibit irregular or excessive movement such as tremors, tics, shaking and/or shivering
- •Participant is Philips employee or their family members residing with this Philips employee.
Outcomes
Primary Outcomes
Clinical safety and effectiveness VSC-MEDlib according to IFU
Time Frame: 2 hours
Clinical safety and effectiveness of the non-invasive and contactless measurement of PR by the VSC-MEDlib within the intended use.